HopeStage
Back to all studies
TerminatedNCT01598896

Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia

Medication studyAges 18–45United States
The study in practice

Understand this study

Who could participate?

Listed age limits: 18 years to 45 years.

Listed locations
BelmontSee all locations and recruitment
Study phase
Phase 2 / Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateMay 2012
Recruitment status
Terminated
Enrollment listed in the registry
12
Sponsor
Mclean Hospital
Sponsor type
Hospital / academic medical center
Study type
Drug
Intervention type
Drug
Study phase
Phase 2 / Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
Locations
United States
Age range
From 18 Years to 45 Years
Official registry ID
NCT01598896
Official title
Show the full official title

Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia

Recruitment & locations

Terminated

Belmont

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Mclean Hospital, a hospital or academic medical center.

Does this study involve medication?

Yes. The study involves medication, including Dronabinol, Clonidine and Placebo.

Who can participate?

Listed age limits: 18 years to 45 years.

Is this study still recruiting?

The registry lists this study as terminated.

Want to explore more studies?

Explore studies